Avistone Reveals Clinical Research Outcomes on c-MET and EGFR Inhibitors Combination in NSCLC at 2024 WCLC

Beijing Avistone Biotechnology Co., Ltd., an innovative company specializing in precision oncology therapeutics, has shared promising results from a recent presentation at the IASLC 2024 World Conference on Lung Cancer in San Diego, CA. The presentation highlighted the clinical combination of two novel inhibitors targeting c-MET and EGFR in patients with non-small cell lung cancer (NSCLC) who have EGFR mutation-positive, MET amplification, or MET overexpression.

Dr. Hepeng Shi, Chairman, CEO, and Founder of Avistone, emphasized the significance of this development. He remarked that combining drugs targeting both c-MET and EGFR has historically been challenging but is now showing substantial potential benefits for NSCLC patients. The preliminary clinical outcomes of their combined inhibitors mark a significant advancement in the treatment of these patients.

The presentation detailed the study titled "Vebreltinib plus PLB1004 in EGFR-mutated, NSCLC with MET amplification or MET overexpression following EGFR-TKI." In this study, 44 patients were treated with various doses of Vebreltinib and PLB1004. Specifically, the patient groups received Vebreltinib 100mg with PLB1004 160mg (15 patients), Vebreltinib 150mg with PLB1004 160mg (13 patients), Vebreltinib 200mg with PLB1004 80mg (3 patients), and Vebreltinib 150mg with PLB1004 80mg (13 patients). These patients were part of the overall safety analysis.

Key findings revealed that 36.4% of the patients had brain metastases, and a significant 86.4% had previously undergone treatment with a third-generation EGFR-TKI. Despite these challenging conditions, objective responses were observed across all dosage levels. Partial responses (PRs) were recorded in 59.4% of the evaluable patients (19 out of 32). Among those with brain metastases, the objective response rate (ORR) was notably high at 75% (9 out of 12). Additionally, patients who had previously received third-generation EGFR-TKI treatment showed an ORR of 58.6% (17 out of 29).

The study also monitored treatment-related adverse events (TRAEs), with rash and paronychia being the most common. Importantly, no patients discontinued treatment due to these adverse events.

This clinical trial, identified as NCT06343064, underscores Avistone Biotechnology's commitment to innovative therapies for patients with significant unmet medical needs, particularly in the realm of NSCLC and other solid tumors. The company continues to expand its portfolio and pipeline of targeted therapies, furthering its mission to address critical gaps in cancer treatment.

Beijing Avistone Biotechnology Co., Ltd. remains dedicated to advancing the field of precision oncology therapeutics, aiming to improve outcomes for patients worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!